Sanofi to buy Inhibrx for $2.2 billion in rare disease push
The acquisition is the latest in a string of small- and mid-sized deals as Sanofi looks to double down on innovative medicines and reduce its reliance on the blockbuster asthma medicine Dupixent.
Source: moneycontrol.com